Enoxaparin

Evidence Level: L5

Predicted Indications: 1

Enoxaparin

Pharmacist Assessment Report

One-Sentence Summary

Enoxaparin is a low-molecular-weight heparin originally used for thrombosis-related conditions such as pulmonary embolism, disseminated intravascular coagulation and purpura fulminans. The TxGNN model predicts it may be effective for thrombophilia due to protein C deficiency, autosomal recessive, but currently there are no registered clinical trials and no publications in the compiled data supporting this specific prediction, so the evidence rests on model prediction alone.

Quick Overview

Item	Content
Original Indication	Pulmonary embolism, disseminated intravascular coagulation, purpura fulminans, acquired purpura fulminans (from the knowledge graph; no approved indication text is recorded in the India licence data)
Predicted New Indication	Thrombophilia due to protein C deficiency, autosomal recessive
TxGNN Prediction Score	0.9958
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, enoxaparin is a low-molecular-weight heparin that potentiates antithrombin and mainly inhibits factor Xa. This reduces thrombin generation and so limits clot formation.

In severe (homozygous or compound heterozygous) protein C deficiency, the protein C anticoagulant pathway is lost and thrombin generation goes unchecked. This typically presents as neonatal purpura fulminans. Enoxaparin’s existing indications include purpura fulminans and acquired purpura fulminans, which are closely related protein C pathway disorders. The score for this prediction (0.9958) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Two caveats apply. The mechanism-of-action field is missing, and the TxGNN score is a computational prediction only. No trials or publications were supplied for this specific indication, so clinical use in protein C deficiency cannot be verified from the available data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Enoxaparin has 20 valid single-ingredient registrations and no cancelled ones. Approved indication text is not recorded for any of them. The first five are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
74006	Encoxel 40 Injection	Prefilled syringe, 0.4 ml injection	Not recorded
188112	Renoxa 60mg Injection	Vial, 1 ml injection	Not recorded
80787	Enoxijet 60 Injection	Prefilled syringe, 0.6 ml injection	Not recorded
138259	Macparin 60mg Injection	Vial, 0.6 ml injection	Not recorded
191232	RB 40mg Injection	Vial, 1 injection	Not recorded

Safety Considerations

Contraindications (associations, not label text): liver failure, haematologic disease, thrombocytopenia, heparin-induced thrombocytopenia, blood coagulation disease, haemophilia, antithrombin III deficiency, Glanzmann thrombasthenia, qualitative platelet defect, intracranial or intracerebral haemorrhage, placental abruption, active peptic ulcer disease, ulcerative colitis, inflammatory bowel disease, biliary tract disease, obstructive jaundice, infective endocarditis (including subacute bacterial endocarditis), retinal disease (including diabetic and hypertensive retinopathy, retinitis, diabetic cataract), osteoporosis (including postmenopausal), and arteriosclerosis obliterans.
Drug Interactions: 174 interactions are recorded. Major ones among the 20 listed include:
- Antiplatelet and anti-inflammatory drugs: acetylsalicylic acid, ibuprofen, ketorolac, abciximab
- Thrombolytic: alteplase
- Other drugs: deferasirox, acalabrutinib, trastuzumab emtansine, ibritumomab tiuxetan, tositumomab
Moderate interactions include dexfenfluramine, fenfluramine, sibutramine, sugammadex, aliskiren, radioactive iodide (I-123 and I-131) and topical diclofenac. Most major interactions involve additive bleeding risk.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high and the mechanism is plausible, given the link to purpura fulminans. However, there are no clinical trials or publications for this indication (Evidence Level L5). Package insert warnings and contraindications are also missing, so safety screening cannot proceed.

To proceed, the following is needed:

Package insert warnings and contraindications from the India Pharma website
Mechanism of action data from DrugBank
A literature and trial search for enoxaparin or low-molecular-weight heparin in severe congenital protein C deficiency and neonatal purpura fulminans
A bleeding-risk assessment that accounts for the major drug interactions and the contraindication associations above
Confirmation of the approved indications on the India licences
Route and formulation compatibility assessment for the target population, including neonates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.